Product Details
| Product Name:
TAK-901 |
CAS No.:
934541-31-8 |
| Purity:
99.59% |
Supply Ability:
10g |
| Release date:
2026/07/13 |
Product Introduction
Bioactivity
| Name | TAK-901 |
| Description | TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others. |
| In vivo | A large set of kinase assays showed that TAK-901 inhibited multiple kinases (including FLT3, FGFR and Src family kinases) with IC50 values similar to those of Aurora A and B. TAK-901 inhibited Aurora A-TPX2 and Aurora B-INCENP in a tightly bound manner in a time-dependent manner.TAK-901 inhibited Aurora A-TPX2 and Aurora B-INCENP in a time-dependent manner. TAK-901 inhibited the NFkB and JAK/STAT pathways with submicromolar potency in a panel of pathway-specific reporter gene-based cell models.TAK-901 inhibited cell proliferation in human tumor cell lines from various tissues with IC50s ranging from 40 to 500 nM.TAK-901 inhibited the proliferation of human PC3 prostate cancer and HL60 acute myeloid leukemia cells in human PC3 prostate cancer and HL60 acute myeloid leukemia cells as determined by immunofluorescence and flow cytometry. Myeloid leukemia cells, consistent with Aurora B inhibition.TAK-901 inhibited Flt3 and FGFR2 autophosphorylation in cells with IC50 values close to those of Aurora B as measured by intracellular histidine H3 phosphorylation, whereas the IC50s for inhibition of intracellular Src and Bcr Abl were 20-fold weaker. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 93 mg/mL (184.29 mM), Sonication is recommended.
|
| Keywords | Yes1 | TAK-901 | TAK 901 | JAK3 | Inhibitor | inhibit | FGR | c-Src | CLK2 | AuroraKinase | Aurora Kinase |
| Inhibitors Related | Ribociclib | Amantadine | 2-Chloropyrazine | Kojic acid | Ruxolitinib | Abemaciclib | Resveratrol | Dasatinib | Ibrutinib | Palbociclib | 2,4,6-Trihydroxybenzoic acid | Lentinan |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-13 |
|
|
|
VIP2Y
|
Xi an Biohorlden Industry Trade Co Ltd
|
2026-07-08 |
|
|
$38.00
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-26 |
|
|
$1000.00
|
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States